|
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 55.61 USD | -0.77% |
|
-2.54% | +26.92% |
| 13/07 | Analyst recommendations: Biogen, Deckers Outdoor, Fortinet, Marathon Petroleum, UnitedHealth… | |
| 07/07 | RBC Capital Adjusts Exelixis Price Target to $46 From $43, Maintains Sector Perform Rating | MT |
| Fiscal Period: December | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
Profitability | ||||||||||
Return on Assets | 7.54 | 4.43 | 3.55 | 14.64 | 19.27 | |||||
Return on Total Capital | 8.54 | 5.07 | 4.13 | 17.46 | 23.14 | |||||
Return On Equity % | 11.3 | 7.76 | 8.74 | 23.13 | 35.53 | |||||
Return on Common Equity | 11.3 | 7.76 | 8.74 | 23.13 | 35.53 | |||||
Margin Analysis | ||||||||||
Gross Profit Margin % | 96.32 | 96.41 | 96.04 | 96.49 | 96.39 | |||||
SG&A Margin | 27.99 | 28.54 | 29.65 | 22.69 | 22.36 | |||||
EBITDA Margin % | 20.93 | 13.8 | 10.74 | 33.14 | 39.73 | |||||
EBITA Margin % | 19.98 | 12.51 | 9.34 | 31.81 | 38.48 | |||||
EBIT Margin % | 19.98 | 12.51 | 9.34 | 31.81 | 38.48 | |||||
Income From Continuing Operations Margin % | 16.1 | 11.31 | 11.35 | 24.04 | 33.73 | |||||
Net Income Margin % | 16.1 | 11.31 | 11.35 | 24.04 | 33.73 | |||||
Net Avail. For Common Margin % | 16.1 | 11.31 | 11.35 | 24.04 | 33.73 | |||||
Normalized Net Income Margin | 12.81 | 9.09 | 8.79 | 22.1 | 25.91 | |||||
Levered Free Cash Flow Margin | 17.45 | 9.16 | 6.85 | 21.41 | 27.2 | |||||
Unlevered Free Cash Flow Margin | 17.45 | 9.16 | 6.85 | 21.41 | 27.2 | |||||
Asset Turnover | ||||||||||
Asset Turnover | 0.6 | 0.57 | 0.61 | 0.74 | 0.8 | |||||
Fixed Assets Turnover | 11.06 | 6.51 | 5.17 | 6.63 | 8.44 | |||||
Receivables Turnover (Average Receivables) | 6.47 | 6.48 | 8.09 | 8.63 | 8.4 | |||||
Inventory Turnover (Average Inventory) | 2.18 | 1.91 | 2.87 | 3.84 | 3.8 | |||||
Short Term Liquidity | ||||||||||
Current Ratio | 5.43 | 4.99 | 3.34 | 3.63 | 3.56 | |||||
Quick Ratio | 5.19 | 4.72 | 3.16 | 3.45 | 3.35 | |||||
Operating Cash Flow to Current Liabilities | 1.19 | 1.12 | 0.85 | 1.73 | 2.18 | |||||
Days Sales Outstanding (Average Receivables) | 56.41 | 56.35 | 45.09 | 42.43 | 43.45 | |||||
Days Outstanding Inventory (Average Inventory) | 167.29 | 191.59 | 127.35 | 95.35 | 96.1 | |||||
Average Days Payable Outstanding | 147.15 | 163.05 | 214.32 | 162.01 | 149.12 | |||||
Cash Conversion Cycle (Average Days) | 76.54 | 84.88 | -41.89 | -24.23 | -9.57 | |||||
Long Term Solvency | ||||||||||
Total Debt/Equity | 2.55 | 8.35 | 9.53 | 9.62 | 9.3 | |||||
Total Debt / Total Capital | 2.49 | 7.71 | 8.7 | 8.77 | 8.51 | |||||
LT Debt/Equity | 2.32 | 7.64 | 8.39 | 8.5 | 8.01 | |||||
Long-Term Debt / Total Capital | 2.26 | 7.05 | 7.66 | 7.76 | 7.33 | |||||
Total Liabilities / Total Assets | 15.5 | 18.98 | 23.06 | 23.87 | 24.02 | |||||
EBIT / Interest Expense | - | - | - | - | - | |||||
EBITDA / Interest Expense | - | - | - | - | - | |||||
(EBITDA - Capex) / Interest Expense | - | - | - | - | - | |||||
Total Debt / EBITDA | 0.18 | 0.85 | 0.93 | 0.29 | 0.21 | |||||
Net Debt / EBITDA | -4.58 | -4.52 | -3.35 | -2.03 | -1.53 | |||||
Total Debt / (EBITDA - Capex) | 0.23 | 0.96 | 1.12 | 0.3 | 0.21 | |||||
Net Debt / (EBITDA - Capex) | -5.78 | -5.09 | -4.06 | -2.11 | -1.55 | |||||
Growth Over Prior Year | ||||||||||
Total Revenues, 1 Yr. Growth % | 45.31 | 12.27 | 13.6 | 18.49 | 6.98 | |||||
Gross Profit, 1 Yr. Growth % | 45.29 | 12.38 | 13.17 | 19.05 | 6.88 | |||||
EBITDA, 1 Yr. Growth % | 151.92 | -25.95 | -11.58 | 265.59 | 28.24 | |||||
EBITA, 1 Yr. Growth % | 160.46 | -29.71 | -15.19 | 303.75 | 29.39 | |||||
EBIT, 1 Yr. Growth % | 160.46 | -29.71 | -15.19 | 303.75 | 29.39 | |||||
Earnings From Cont. Operations, 1 Yr. Growth % | 106.71 | -21.11 | 13.98 | 150.89 | 50.13 | |||||
Net Income, 1 Yr. Growth % | 106.71 | -21.11 | 13.98 | 150.89 | 50.13 | |||||
Normalized Net Income, 1 Yr. Growth % | 124.82 | -20.33 | 9.89 | 197.83 | 25.39 | |||||
Diluted EPS Before Extra, 1 Yr. Growth % | 105.71 | -22.22 | 16.07 | 170.77 | 57.95 | |||||
Accounts Receivable, 1 Yr. Growth % | 75.7 | -24.01 | 10.53 | 11.81 | 8.09 | |||||
Inventory, 1 Yr. Growth % | 31.09 | 21.12 | -47.98 | 29.24 | -3.14 | |||||
Net Property, Plant and Equip., 1 Yr. Growth % | 35.11 | 131.6 | 4.79 | -19.34 | -11.63 | |||||
Total Assets, 1 Yr. Growth % | 22.41 | 17.4 | -4.2 | 0.18 | -3.5 | |||||
Tangible Book Value, 1 Yr. Growth % | 18.26 | 12.94 | -9.26 | -0.9 | -3.8 | |||||
Common Equity, 1 Yr. Growth % | 17.64 | 12.57 | -9.02 | -0.87 | -3.69 | |||||
Cash From Operations, 1 Yr. Growth % | 91.79 | -9.53 | -8.08 | 110 | 26.33 | |||||
Capital Expenditures, 1 Yr. Growth % | 111.65 | -48.91 | 46.07 | -29.74 | -70.36 | |||||
Levered Free Cash Flow, 1 Yr. Growth % | 86.37 | -41.08 | -15.01 | 270.2 | 35.96 | |||||
Unlevered Free Cash Flow, 1 Yr. Growth % | 86.37 | -41.08 | -15.01 | 270.2 | 35.96 | |||||
Compound Annual Growth Rate Over Two Years | ||||||||||
Total Revenues, 2 Yr. CAGR % | 21.77 | 27.73 | 12.94 | 16.02 | 12.59 | |||||
Gross Profit, 2 Yr. CAGR % | 21.6 | 27.78 | 12.77 | 16.07 | 12.8 | |||||
EBITDA, 2 Yr. CAGR % | -10.85 | 36.58 | -19.09 | 79.79 | 116.53 | |||||
EBITA, 2 Yr. CAGR % | -11.92 | 35.3 | -22.79 | 85.05 | 128.56 | |||||
EBIT, 2 Yr. CAGR % | -11.92 | 35.3 | -22.79 | 85.05 | 128.56 | |||||
Earnings From Cont. Operations, 2 Yr. CAGR % | -15.16 | 27.7 | -5.18 | 69.11 | 94.08 | |||||
Net Income, 2 Yr. CAGR % | -15.16 | 27.7 | -5.18 | 69.11 | 94.08 | |||||
Normalized Net Income, 2 Yr. CAGR % | -14.04 | 33.83 | -6.43 | 80.91 | 93.25 | |||||
Diluted EPS Before Extra, 2 Yr. CAGR % | -15.98 | 26.49 | -4.99 | 77.28 | 106.81 | |||||
Accounts Receivable, 2 Yr. CAGR % | 53.39 | 15.55 | -8.35 | 11.17 | 9.93 | |||||
Inventory, 2 Yr. CAGR % | 46.07 | 26 | -20.62 | -18 | 11.89 | |||||
Net Property, Plant and Equip., 2 Yr. CAGR % | 28.22 | 76.89 | 55.78 | -8.07 | -15.58 | |||||
Total Assets, 2 Yr. CAGR % | 17.79 | 19.88 | 6.05 | -2.04 | -1.68 | |||||
Tangible Book Value, 2 Yr. CAGR % | 15.04 | 15.57 | 1.23 | -5.17 | -2.36 | |||||
Common Equity, 2 Yr. CAGR % | 14.51 | 15.08 | 1.2 | -5.03 | -2.29 | |||||
Cash From Operations, 2 Yr. CAGR % | -12.79 | 31.72 | -8.81 | 38.94 | 62.88 | |||||
Capital Expenditures, 2 Yr. CAGR % | 123.7 | -4.45 | -13.61 | 1.31 | -54.36 | |||||
Levered Free Cash Flow, 2 Yr. CAGR % | -17.7 | 4.79 | -29.23 | 77.38 | 124.35 | |||||
Unlevered Free Cash Flow, 2 Yr. CAGR % | -17.7 | 4.79 | -29.23 | 77.38 | 124.35 | |||||
Compound Annual Growth Rate Over Three Years | ||||||||||
Total Revenues, 3 Yr. CAGR % | 18.89 | 18.52 | 22.83 | 14.76 | 12.93 | |||||
Gross Profit, 3 Yr. CAGR % | 18.6 | 18.45 | 22.71 | 14.83 | 12.92 | |||||
EBITDA, 3 Yr. CAGR % | -12.28 | -16.2 | 18.15 | 33.77 | 60.64 | |||||
EBITA, 3 Yr. CAGR % | -13.31 | -18.3 | 15.8 | 34.01 | 64.24 | |||||
EBIT, 3 Yr. CAGR % | -13.31 | -18.3 | 15.8 | 34.01 | 64.24 | |||||
Earnings From Cont. Operations, 3 Yr. CAGR % | -30.56 | -17.19 | 22.95 | 31.15 | 62.53 | |||||
Net Income, 3 Yr. CAGR % | -30.56 | -17.19 | 22.95 | 31.15 | 62.53 | |||||
Normalized Net Income, 3 Yr. CAGR % | -13.42 | -16.19 | 25.32 | 37.64 | 60.1 | |||||
Diluted EPS Before Extra, 3 Yr. CAGR % | -31.19 | -18.12 | 22.92 | 34.71 | 70.59 | |||||
Accounts Receivable, 3 Yr. CAGR % | 20.2 | 21.37 | 13.85 | -2.07 | 10.13 | |||||
Inventory, 3 Yr. CAGR % | 40.85 | 37.23 | -6.17 | -6.62 | -13.32 | |||||
Net Property, Plant and Equip., 3 Yr. CAGR % | 37.99 | 56.15 | 48.56 | 25.09 | -9.27 | |||||
Total Assets, 3 Yr. CAGR % | 22.53 | 17.66 | 11.24 | 4.06 | -2.53 | |||||
Tangible Book Value, 3 Yr. CAGR % | 20.61 | 14.34 | 6.62 | 0.52 | -4.72 | |||||
Common Equity, 3 Yr. CAGR % | 19.75 | 13.86 | 6.41 | 0.5 | -4.59 | |||||
Cash From Operations, 3 Yr. CAGR % | -1.21 | -11.71 | 16.84 | 20.42 | 34.6 | |||||
Capital Expenditures, 3 Yr. CAGR % | 24.48 | 29.24 | 10.07 | -19.36 | -32.74 | |||||
Levered Free Cash Flow, 3 Yr. CAGR % | 12.76 | -26.37 | -2.27 | 22.85 | 62.33 | |||||
Unlevered Free Cash Flow, 3 Yr. CAGR % | 12.76 | -26.37 | -2.27 | 22.85 | 62.33 | |||||
Compound Annual Growth Rate Over Five Years | ||||||||||
Total Revenues, 5 Yr. CAGR % | 49.61 | 28.91 | 16.47 | 17.51 | 18.63 | |||||
Gross Profit, 5 Yr. CAGR % | 49.45 | 28.77 | 16.23 | 17.49 | 18.65 | |||||
EBITDA, 5 Yr. CAGR % | 63.49 | 5.73 | -15.07 | 13.73 | 50.55 | |||||
EBITA, 5 Yr. CAGR % | 60.75 | 3.81 | -17.23 | 13.3 | 51.99 | |||||
EBIT, 5 Yr. CAGR % | 60.75 | 3.81 | -17.23 | 13.3 | 51.99 | |||||
Earnings From Cont. Operations, 5 Yr. CAGR % | 26.9 | 3.4 | -21.34 | 10.18 | 47.58 | |||||
Net Income, 5 Yr. CAGR % | 26.9 | 3.4 | -21.34 | 10.18 | 47.58 | |||||
Normalized Net Income, 5 Yr. CAGR % | 38.65 | 7.96 | -10.69 | 14.01 | 49.03 | |||||
Diluted EPS Before Extra, 5 Yr. CAGR % | 20.77 | 2.57 | -21.71 | 11.53 | 51.35 | |||||
Accounts Receivable, 5 Yr. CAGR % | 47.53 | 22.68 | 7.84 | 17.18 | 12.27 | |||||
Inventory, 5 Yr. CAGR % | 52.46 | 37.98 | 11.98 | 11.68 | 0.67 | |||||
Net Property, Plant and Equip., 5 Yr. CAGR % | 135.23 | 68.09 | 44.85 | 26.33 | 18.5 | |||||
Total Assets, 5 Yr. CAGR % | 34.44 | 36.2 | 15.65 | 9.35 | 5.88 | |||||
Tangible Book Value, 5 Yr. CAGR % | 142.44 | 61.42 | 12.45 | 6.09 | 2.93 | |||||
Common Equity, 5 Yr. CAGR % | 89.98 | 54.25 | 11.95 | 5.89 | 2.84 | |||||
Cash From Operations, 5 Yr. CAGR % | 13.76 | 16.97 | -4.32 | 5.84 | 33.44 | |||||
Capital Expenditures, 5 Yr. CAGR % | 106.68 | 5.56 | 3.98 | 17.25 | -22.6 | |||||
Levered Free Cash Flow, 5 Yr. CAGR % | 73.65 | 9.84 | -6.41 | 4.66 | 36.26 | |||||
Unlevered Free Cash Flow, 5 Yr. CAGR % | 133.25 | 8.59 | -6.41 | 4.66 | 36.26 |
- Stock Market
- Stocks
- EXEL Stock
- Financials Exelixis, Inc.
- Financial Ratios
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition















